B-Myb, a highly conserved member of the Myb oncoprotein family, is a 110 kDa sequence-speci®c DNA binding protein expressed in virtually all proliferating cells. B-myb expression reaches its maximum at the G1/S phase boundary and during the S phase of the cell cycle. We have previously shown that B-Myb activity is cell cycle regulated and it is controlled by the antagonistic eects of cyclin D1 and A. Here we show that ectopic expression of cyclin A causes a pronounced reduction of B-Myb protein level. We provide evidence that in addition to triggering B-Myb activity an important eect of cyclin A is to facilitate multiple ubiquitination of B-Myb. The C-terminal domain of BMyb is of key importance in mediating this eect of cyclin A. Contrary to full-length B-Myb, a C-terminal deletion mutant displays activity irrespective of cyclin A expression, does not undergo ubiquitination, and its halflife is not aected by cyclin A. Ectopic expression of either Cdc34 or the F-box protein p45
Introduction
Once cells have emerged from quiescence, progression through the cell division cycle is facilitated by the timely activation of a family of enzymes called the cyclin-dependent kinases (Cdk). Cdk activity is controlled by a network of activating and inhibitory signals, including protein ± protein interactions, posttranslational modi®cations and subcellular localization (Morgan, 1997) . Intrinsic inputs like phosphorylation of Cdks are responsible for timing and coordinating cell cycle events, whereas signals provided by the environment target principally the levels of cyclins and Cdk inhibitors (Solomon and Kaldis, 1998) . Although the role played by Cdks is established, individual events triggered following activation of these kinases are still largely unknown and a restricted number of physiological substrates have so far been identi®ed.
The myb transcriptional regulators comprise a family of related nuclear DNA-binding proteins, which display high homology in their DNA-binding domains. Members of this family have been identi®ed in mammals, avians, insects, yeast, slime mold and plants (Graf, 1992) . The protein encoded by B-myb (B-Myb) is a sequence speci®c DNA binding factor, which diers from the other members of the vertebrate Myb family, c-Myb and A-Myb, in that it displays extremely weak or undetectable transactivation activity (Nomura et al., 1988; Mizuguchi et al., 1990; Bouwmeester et al., 1992; Foos et al., 1992; Lam et al., 1992; Watson et al., 1993) . The lack of transactivation activity has initially suggested that B-Myb is an inhibitory member of the Myb family (Foos et al., 1992; Watson et al., 1993) . Recent evidence indicated that B-Myb plays an important role during cell cycle progression in most, if not all cell types. In contrast to c-and A-myb, whose function appears to be restricted to speci®c cell types, B-myb is expressed in virtually all proliferating cells and tissues (Nomura et al., 1988; Bouwmeester et al., 1992; Foos et al., 1992; Lam et al., 1992; Kamano et al., 1995) . During mouse embryonic development expression of B-myb is tightly linked to cell proliferation (Sitzmann et al., 1996) . B-myb de®cient mice die at a very early stage of development due to failure to form the inner cell mass in the blastocyst (Tanaka et al., 1999) . B-myb expression is controlled by transcription factor E2F and reaches its maximum at the G1/S phase boundary and during the S phase of the cell cycle Zwicker et al., 1996) . Treatment of cells with B-myb antisense oligonucleotides results in inhibition of cell proliferation (Arsura et al., 1992; Sala and Calabretta, 1992) . Accordingly, overexpression of B-myb overrides p53-p21 Waf1 -mediated cell cycle arrest (Lin et al., 1994) . Evidence obtained in our and other laboratories (Ansieau et al., 1997; Lane et al., 1997; Sala et al., 1997) indicates that cyclin A/Cdk2-mediated phosphorylation triggers B-Myb transactivation activity without aecting DNA-binding activity . Mapping of the sites of phosphorylation revealed that they are located at the C-terminus of BMyb (Saville and Watson, 1998; Bartsch et al., 1999) . B-Myb C-terminal domain can be envisaged as a cell cycle sensor that inhibits transactivation whereas phosphorylation at the onset of S phase apparently counteracts the internal inhibition .
The product of genes playing essential functions in the cell cycle are tightly regulated at a number of levels, including transcription, mRNA stability, translation and post-translation. An additional level of control is the regulation of protein stability (Rechstei-ner and Rogers, 1996) . The rapid and controlled destruction of proteins keeps their intracellular levels responsive to internal or external signals. In most instances, proteins are targeted to rapid destruction by conjugation to ubiquitin, a highly conserved small protein. The ubiquitination pathways are complex, but essentially consist of recognition of a substrate by the ubiquitination machinery, covalent attachment of a poly-ubiquitin chain and channeling of the ubiquitinated substrate to the 26S proteasome (Varshavsky, 1997) . High selectivity is crucial in this process and this is guaranteed by E2, ubiquitin-conjugating enzymes and E3, ubiquitin ligases. A number of cell cycle components (Pagano et al., 1995; Hengst and Reed, 1996; Diehl et al., 1997; Hershko, 1997; Hashemolohosseini et al., 1998) as well as transcription factors (Curran et al., 1984; Treier et al., 1994; Hateboer et al., 1996; Hofmann et al., 1996; Campanero and Fleming, 1997; Salghetti et al., 1999) and activators of transcription (Kitagawa et al., 1999 ) are short-lived proteins whose abundance is regulated by the ubiquitin pathway. The role played by tight control of protein abundance in the regulation of cell proliferation is underscored by the fact that some oncogenic forms of cyclins (Lebwohl et al., 1994) and regulators of transcription (Treier et al., 1994; Chan et al., 1999; Salghetti et al., 1999) escape degradation and accumulate to high levels in the cell. Likewise, enhanced degradation of tumor suppressors like p27
Kip1 correlates with tumor aggressiveness (Esposito et al., 1997; Loda et al., 1997) .
In this study we have investigated the mechanism of B-Myb degradation. The reduction of B-Myb protein observed upon ectopic expression of cyclin A suggested a role for proteolytic degradation pathways. This has prompted us to examine the involvement of ubiquitination in the process of B-Myb degradation and the physical and functional interaction with components of the Cdc34-SCF p45Skp2 pathway.
Results

Cyclin A affects B-Myb abundance
Among the members of the Myb family B-Myb displays very weak transactivation activity (Foos et al., 1992; Watson et al., 1993) . Evidence obtained in our laboratory indicated that B-Myb activation is phosphorylation-dependent and that transactivation by B-Myb is speci®cally triggered upon expression of cyclin A Bartsch et al., 1998) . Multiple phosphorylation of B-Myb causes a 2 ± 3-fold increase in transactivation activity (Figure 1b ) but also aects B-Myb cellular level ( Figure 1a ). Contrary to wildtype B-Myb, the activity of a C-terminally truncated, constitutive active form of B-Myb (BMyb 1 ± 508 ) was slightly aected by co-expressed cyclin A (50.2-fold, Figure 1b ) and the protein amount remained unchanged (Figure 1a ). Immuno¯uorescence studies showed that both full-length B-Myb and the deletion mutant were in the nucleus (Figure 1c ). This indicates that lack of the C-terminal domain does not alter the localization of B-Myb 1 ± 508 and dierences in protein stability cannot be ascribed to changes in subcellular compartmentalization. The fact that BMyb 1 ± 508 ( Figure 1a ) as well as an unrelated protein (PCTAIRE-1, data not shown) were unaected by cyclin A indicates that ectopic expression of cyclin A per se does not trigger degradation of cellular proteins in an unspeci®c manner. To assess whether cyclin A-dependent eects on fulllength B-Myb result in shortening of the protein's halflife, we expressed full-length or C-terminally deleted BMyb in 293 HEK cells in the presence or the absence of cyclin A. Twenty hours after transfection cells were treated with cycloheximide (CHX) and extracts were made at dierent times thereafter. Figure 2 shows the analysis of immunoprecipitated full-length or Cterminally deleted B-Myb. The data indicate that the half-life of full-length B-Myb is substantially decreased 
Inhibitors of the proteasome rescue B-Myb from degradation
The data presented in Figure 2 show that B-Myb turnover rate is clearly accelerated upon co-expression of cyclin A. To further substantiate this ®nding, we carried out studies with the proteasome inhibitors, NAcetyl-Leu-Leu-norLeucinal (LLnL) and Lactacystin. (Figure 3a , lane 3 vs 4), whereas the inhibitor displayed a less pronounced eect in the absence of the cyclin (Figure 3a , lane 1 vs 2). On the contrary, the protein level of the C-terminal deletion mutant was unaected by LLnL (Figure 3b ).
The use of small size inhibitors in the elucidation of biochemical pathways is sometimes thwarted by unpredictable non-speci®c eects, such as interference with metabolic pathways and/or cellular functions that are unrelated to the target of action. This is the case for cycloheximide, that in addition to blocking protein synthesis has been reported to superinduce gene transcription (Mahadevan and Edwards, 1991) . To rule out non-speci®c eects of the proteasome inhibitors on the level of B-myb mRNA that would result in changes in the protein level, we puri®ed total RNA from 293 HEK cells treated in the presence or the absence of LLnL. Northern blot analysis was carried with a 32 P-labeled probe speci®c to B-myb. Figure 3c shows that LLnL treatment did not cause an increase of B-myb mRNA. Non-speci®c stabilization of cellular proteins by LLnL has been ruled in a previous study (Hashemolhosseini et al., 1998) and was con®rmed here by examining the level of a protein unrelated to B-Myb (PCTAIRE-1, data not shown) in LLnL-treated versus non treated cells.
B-Myb is poly-ubiquitinated upon co-expression with cyclin A
To address the question of how B-Myb accumulation is decreased upon co-transfection with cyclin A, we examined the possible involvement of ubiquitinmediated pathways. To this aim 293 HEK cells were co-transfected with B-Myb and HA-tagged ubiquitin in the presence or the absence of cyclin A. Cells were extracted in a buer containing 1% SDS and immediately boiled (Hofmann et al., 1996) in order to block degradation of ubiquitinated proteins and facilitate disaggregation of protein complexes. Extracts were immunoprecipitated with an antibody speci®c to BMyb and proteins separated on a SDS-polyacrylamide gel. Western blot analysis carried out with a monoclonal antibody to the HA-tag indicated that B-Myb is heavily ubiquitinated only when it is expressed in the presence of cyclin A ( Figure 4 , lower left). The laddering pattern reported for some poly-ubiquitinated proteins (Pagano et al., 1995) could not be observed with the B-Myb antibody used in this study. Lack of discrete patterns of bands was also described for other ubiquitinated protein (Hateboer et al., 1996) and is likely due to hindering of the antigenic sites by ubiquitin. Contrary to wildtype BMyb, the C-terminal deletion mutant B-Myb 1 ± 508 displayed very weak ubiquitination, if any ( Figure 4 , lower right). To exclude that this could result from dierences in the level of protein expression, the same membrane was probed with a B-Myb antibody. The results presented in Figure 4 (upper panels) indicate that the weak ubiquitination of B-Myb 1 ± 508 was not due to lack of protein expression. These results indicate that BMyb C-terminal domain confers sensitivity to ubiquitinmediated proteolysis.
B-Myb interacts with SCF p45Skp2
p19 Skp1 and Cul-1 bind to the F-box protein p45 Skp2 to form a complex (SCF) that functions as E3 ubiquitin ligase. The expression and activity of the F-box protein family member p45
Skp2 is cell cycle-dependent and it is maximal at the onset of S phase (Lisztwan et al., 1998) a time when it has been found assembled in a large multicomplex protein with cyclin A/Cdk2 (Zhang et al., 1995) . Considering that SCF may play a key role in the degradation of selected S phase regulatory proteins (Lisztwan et al., 1998) and given that B-Myb expression is maximal in S phase (Bartsch et al., 1998) , we performed co-precipitation studies asking whether p45 Skp2 was controlled by analysing an aliquot of cell extract by Western blot (Figure 5a , lower panels). To rule out the possibility that interaction between B-Myb and p45
Skp2 described above may result from the abnormal expression of the two proteins, we employed Hs68 ®broblasts ®rst synchronized by a serum-starvation-release protocol and then enriched for S phase cells upon release from a subsequent hydroxyurea block (Charrasse et al., 1999) . Also in this case, co-precipitation of endogenous BMyb and p45
Skp2 was observed (Figure 5b ). Identical results were obtained by employing non-transfected, synchronized HeLa cells (Charrasse et al., 1999) released from a hydroxyurea block (data not shown).
To further examine the involvement of the Cdc34-SCF pathway in the degradation of B-Myb, we cotransfected 293 HEK cells with B-Myb and cyclin A in the presence or the absence of human Cdc34. Evidence obtained by studies in vitro as well as in yeast indicates that the latter is the E2 component of this speci®c ubiquitination pathway. The results presented in Figure   Figure 4 B-Myb is poly-ubiquitinated. 293 HEK cells were transfected with wildtype or C-terminally deleted B-Myb and HAubiquitin in the presence or the absence of cyclin A. Cells were extracted in a buer containing 50 mM Tris-HCl, pH 7.5, 5 mM dithiothreitol (DTT), 1% sodium dodecylsulfate (SDS) and processed as described in Materials and methods. The amount of protein that underwent immunoprecipitation was corrected for transfection eciency. Western blot analysis was carried out with B-Myb polyclonal antibody (upper panels) or with anti-HA tag monoclonal antibody (lower panels). The migration of full-length B-Myb and B-Myb deletion mutant is indicated. The ®rst lane shows cells transfected with HA-ubiquitin alone 
Discussion
A large body of evidence indicates that B-Myb, a highly conserved member of the Myb transcription factor family, plays a key role in cell proliferation. Recent studies from our Bartsch et al., 1998 Bartsch et al., , 1999 and other laboratories (Ansieau et al., 1997; Lane et al., 1997; Sala et al., 1997; Saville and Watson, 1998) extended these observations, showing that B-Myb activity is regulated in a cell cycle-dependent manner and is the result of the interplay of cyclin D1 (Horstmann et al., 2000) and cyclin A eects. The experiments described here address another aspect of the regulation of B-Myb, namely the mechanism responsible for its degradation. We observed that the eect of cyclin A/Cdk2-mediated phosphorylation on B-Myb is twofold: (i) an increase of B-Myb transactivation activity; and (ii) a reduction of the total amount of B-Myb protein. Kinetic studies showed that the eect of cyclin A on B-Myb level increases with time of expression. However, we observed that prolonged expression of B-Myb selectively causes apoptosis in the transfected cells (data not shown). For this reason the study presented here was conducted in conditions of lack of any detectable apoptosis. Reduction of cellular protein amount may be explained by eects at the transcriptional, translational and/or post-translational level. In this study we have addressed the role of post-translational mechanisms on B-Myb stability. The experiments reported here con®rm that B-Myb protein stability is aected by the presence of cyclin A, which causes a sharp decrease of B-Myb half-life from 2.7 h to 50 min. On the contrary, the half-life of a C-terminally deleted form of B-Myb, which displays high transactivation activity regardless of cyclin A expression, is only slightly aected by cyclin A. This C-terminally deleted mutant results to be more stable (T 1/2 =2.5 h) than the activated wildtype B-Myb (T 1/2 =50 min), indicating that a direct correlation between activation and rapid destruction applies only to full-length B-Myb and is a function of the presence of the C-terminus. Experiments conducted in the presence of proteasome inhibitors showed that treatment with these compounds rescues degradation of full-length B-Myb without substantially aecting the stability of the C-terminal deletion mutant. The eect of proteasome inhibitors on wt B-Myb was particularly evident in cells cotransfected with cyclin A. The issue on whether treatment of cells with proteasome inhibitors may result in non-speci®c eects on cellular mRNA and protein level was ruled out by examining in detail the eect of LLnL. The results obtained allowed us to exclude secondary eects of the drug. Taken together, these data support the hypothesis that the dierent response of wildtype and C-terminally deleted B-Myb to cyclin A relies on the presence of the C-terminal domain.
The results presented here show that B-Myb is heavily ubiquitinated when cyclin A is co-expressed. The C-terminal regulatory domain appears to play a central role in this process since deletion of this region drastically reduces ubiquitination of B-Myb. On the other hand, deletion of the DNA-binding domain that is located at the N-terminus of the protein does not aect the pattern of ubiquitination (data not shown). Proteolysis mediated by the ATP-dependent ubiquitin system is widely used in the cell since it provides a very eective and irreversible control of the steady state of key components of the cell cycle machinery Koepp et al., 1999) . Multiple ubiquitination of proteins occurs via a cascade of ubiquitin-transfer reactions that involve three components: a ubiquitin-activating enzyme (E1), a conjugating enzyme (E2) and a protein ligase (E3). The latter is largely responsible for substrate recognition and confers speci®city to the system (Hershko, 1997; Laney and Hochstrasse, 1998) . Two pathways operating at the G1/S and G2/M transition account for the major ubiquitination activities so far identi®ed. This prompted us to examine the possible involvement of one of these ubiquitination pathways in B-Myb degradation. One type of SCF complex functions as E3 ubiquitin ligase at the onset of S phase and it is composed by p19
Skp1 , Cul-1 and the F-box protein p45
Skp2 Koepp et al., 1999) . The F-box protein is believed to be responsible for recognition and recruitment of the substrate to ubiquitinate. The data presented here provide evidence for physical and functional interaction between B-Myb and components of this pathway. Physical interaction with p45
Skp2 was observed upon immunoprecipitation of B-Myb or p45
Skp2 from transiently transfected cells. More importantly, we observed association between the two proteins in non-transfected cells synchronized in S phase, a time in the cell division cycle when the Skp2 is maximal (Bartsch et al., 1998; Lisztwan et al., 1998) . An important question that we addressed at this point was the physiological signi®cance of such association. The functional involvement of SCF p45Skp2 in the turnover of endogenous B-Myb was examined in cells ectopically expressing p45
Skp2
. The results obtained indicate that p45
Skp2 causes a reduction of the level of endogenous B-Myb. Pursuing this line of evidence, we moved one step up in testing the involvement of the SCF p45Skp2 pathway in B-Myb destruction and carried out over-expression studies with the E2 component of this ubiquitination cascade, namely human Cdc34. These showed that expression of Cdc34 results in reduction of B-Myb protein level, particularly upon cyclin A-dependent activation of B-Myb. Taken together, our data suggest a role for the SCF p45Skp2 pathway in B-Myb turnover. Ubiquitinated proteins can be distinguished into two classes: those whose destruction is essential for cell cycle progression, and those whose degradation is rather required for controlling the timing of subsequent transitions and the correct alternation of cell divisions (Koepp et al., 1999) . According to this de®nition B-Myb, like E2F-1 and other nuclear transcription factors involved in the regulation of cell proliferation, belongs to the second class. Changes in the stability of nuclear proto-oncogenes and tumor suppressor genes have been linked to increased transformation and tumor aggressiveness (Isaksson et al., 1996; Loda et al., 1997) . Studies on the proto-oncogene c-Myb showed that deletion of the C-terminal domain gives rise to an isoform displaying increased stability (Bies and Wol, 1997) and transforming activity in model systems (Graesser et al., 1991) . Clinical studies con®rmed that truncated c-Myb is expressed in chronic myelogenous leukemia cells and this form displays elevated transactivation activity compared to wildtype c-Myb (Tomita et al., 1998) . This evidence has led to the suggestion that by increasing both activity and protein stability, Cterminal deletion of c-Myb may contribute to the pathogenesis of human leukemias. Also in the case of A-and B-Myb, deletion of the C-terminal domain gives rise to forms displaying constitutive activity . We have shown here that constitutive active, Cterminally truncated B-Myb is more stable than the full-length protein activated by physiological stimuli, such as cyclin A/Cdk2 phosphorylation. This indicates that B-Myb C-terminal domain is not only target of activating signals at the onset of S phase, but it allows the cell to keep a tight temporal control of B-Myb activity by sensing signals that direct BMyb to rapid destruction. This double control is apparently lost upon truncation of the C-terminus. The possible role of B-Myb in cellular transformation is now beginning to be explored (Sala and Watson, 1999) and our study suggests that, as for c-Myb, the expression of C-terminally deleted B-Myb forms should be considered.
The evidence so far available indicates that B-Myb transactivation activity is the result of the interplay of cyclin D1 and cyclin A eects (Horstmann et al., 2000; Lane et al., 1997; Sala et al., 1997; . According to these data, the synthesis of cyclin D1 in mid-G1 and its Cdk4-independent interaction with B-Myb (Horstmann et al., 2000) would provide a means to maintain B-Myb in an inactive form. Degradation of cyclin D1 at the onset of S phase, and the subsequent hyperphosphorylation of B-Myb mediated by cyclin A/Cdk2, likely cause release of the negative constraint set by B-Myb C-terminal domain leading to triggering of transactivation activity. The role played by Cdk2 in this process appears to be essential since the expression of a kinase-negative Cdk2 mutant results in the suppression of B-Myb phosphorylation Lane et al., 1997) . The new ®ndings reported here add yet another step to this model. The data show that upon cyclin A-mediated activation B-Myb is poly-ubiquitinated, a process likely mediated by the SCF p45Skp2 pathway, and this ultimately targets B-Myb to rapid degradation (Figure 7) . Also in the process of B-Myb degradation Cdk2-dependent phosphorylation plays a key role, since the expression of a kinase-negative Cdk2 mutant facilitates rescuing of B-Myb from degradation (data not shown and . It will now be interesting to examine whether phosphorylation of B-Myb C-terminal domain at particular sites is responsible for the rapid processing of B-Myb.
Materials and methods
Expression vectors and antibodies
Expression vectors for full-length (pMuBME69A+) and a C-terminal deletion mutant of mouse B-Myb (pMuBM1-508) have been described in detail before (Kamano and Klempnauer, 1997) . The expression vector for cyclin A (pXcycA) was a kind gift of G Draetta (Milano, Italy). Expression vectors for HA-tagged human Cdc34 (pcDNA3-Cdc34) and myc-tagged form of p45 Skp2 were obtained from W Krek (Basel, Switzerland). An expression vector for HAtagged human ubiquitin (pMT107 HA-ubiquitin) was a kind gift of D Bohmann (Heidelberg, Germany). An expression vector for kinase-negative Cdk2 (D 145 -N) was kindly provided by E Harlow (Charlestown, MA, USA).
A rabbit antiserum (Kamano et al., 1995) to the Nterminus of mouse B-Myb was employed to carry out immunoprecipitation experiments. A puri®ed rabbit antibody to B-Myb (N-19, S Cruz Biotech) was employed in immuno¯uorescence studies and Western blot analysis. A rabbit antiserum to human Cdc34 and a monoclonal antibody to p45
Skp2 were gifts of W Krek and J Mestan (Basel, Switzerland). A rabbit polyclonal antiserum to fulllength p45
Skp2 was purchased from S Cruz Biotech and a monoclonal antibody 12CA5 was obtained from Boehringer.
Cell culture and transient transfections
Human embryo kidney (HEK) 293, HeLa, REF52 and Hs68 cells were maintained in DMEM (Dulbecco's Modi®ed Eagle Medium) (Gibco) containing 10% (v/v) fetal calf serum (BioWhittaker) and penicillin/streptomycin (100 U/ml and 100 mg/ml, respectively).
Hs68 were made quiescent by serum deprivation (30 ± 48 h) and restimulated with 10% FCS for 20 h. Synchronization of Hs68 cells in S phase was obtained as described (Charrasse et al., 1999) . HeLa cells were synchronized by double thymidine block. Brie¯y, 4610 5 cells were seeded in 100 mm plates and allowed to grow for 36 h. Thymidine (2 mM) was added to cultures for 14 h, cells were released from the block by washing three times with medium and after 8 h thymidine was added again. Upon a second treatment for 14 h cells were harvested. Cell cycle progression was monitored by FACS analysis as described (Charrasse et al., 1999) .
HEK 293 cells were transiently transfected with the FuGENE 6 kit as described by the supplier (Boehringer Mannheim) 24 h after seeding, when cells reached approximately 50 ± 60% con¯uence. The amount of expression vectors used for 3.5 cm tissue culture dishes was: B-Myb wt or deletion mutant (0.4 mg); cyclin A (0.2 mg); HA-ubiquitin (0.1 mg); HA-Cdc34 (0.2 mg). When HeLa cells were transfected with p45
Skp2 to examine the eect on endogenous proteins, 2 mg of expression vector was employed. Synchronization of transfected cells was carried out as described above. To correct for dierences in transfection eciency plates were co-transfected with 0.3 mg of the pCMV-bgalactosidase reporter gene (Clontech). Transactivation activity was measured by transfecting cells with 0.35 mg of the Myb-responsive luciferase reporter gene p3Atk-Luc .
Proteasome inhibitors treatment and protein half-life determination
The proteasome inhibitors LLnL and Lactacystin were prepared as 5 mM and 10 mM stock solutions in DMSO, respectively, and stored at 7208C. LLnL (50 mM) or Lactacystin (10 mM) was added to the transfected cells 6 h prior to harvesting. Cycloheximide (CHX) was dissolved in phosphate-buered saline (PBS) at 10 mg/ml just prior to use. Half-life determination of full-length and deleted B-Myb mutant was carried out by addition of CHX (35.5 mM) 20 h after transfection of the cells. Cells were harvested and extracted at dierent times thereafter.
Western blot analysis and immunoprecipitation
Cells cultured in 3.5 cm tissue culture plate were washed twice with ice-cold PBS and lysed in 0.1 ml ice-cold Buer A (50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 20 mM NaF, 1 mM EDTA, 6 mM EGTA, 15 mM sodium pyrophosphate, 15 mM p-nitrophenyl phosphate (pNPP), 0.5 mM sodium orthovanadate, 1 mM benzamidine, 0.1 mM phenylmethylsulfonyl uoride (PMSF), 1% Nonidet P-40). Samples were processed and luciferase activity was determined as described . To examine protein ubiquitination, transfected cells were lysed in Buer B (50 mM Tris-HCl, pH 7.5, 5 mM dithiothreitol (DTT), 1% sodium dodecylsulfate (SDS)) and immediately boiled as previously described (Hofmann et al., 1996) . Samples were clari®ed by centrifugation for 10 min at 14 000 r.p.m. in an Eppendorf centrifuge and diluted with four volumes of Buer A prior to immunoprecipitation.
Detection of B-Myb by Western blot analysis was performed following separation of proteins on 7.5% polyacrylamide gels containing 0.07% bisacrylamide under denaturing conditions as described (Bartsch et al., 1999) . The amount of protein loaded was corrected for transfection eciency. Proteins were transferred to a polyvinylidene di¯uoride membrane (PVDF, Millipore) and the resulting membrane was probed with the appropriate antibody. Reactive bands were revealed using the ECL system (Amersham). Protein quanti®cation was performed employ- Figure 7 Hypothetical model of B-Myb regulation during cell cycle progression. B-Myb is expressed at the onset of S phase and as such can bind DNA (Foos et al., 1992) . At this stage inhibition of transactivation activity is likely the result of intramolecular (Ansieau et al., 1997) as well as protein ± protein interactions (Sala et al., 1996; Horstmann et al., 2000) . Cyclin D1 interacts with BMyb in a Cdk4-independent manner (Horstmann et al., 2000) . Degradation of cyclin D1 at the onset of S phase and the subsequent hyperphosphorylation of B-Myb mediated by cyclin A/Cdk2 likely cause release of the negative constraint set by B-Myb C-terminal domain leading to triggering of transactivation activity. Unfolding of the molecule exposes internal domains facilitating multiple ubiquitination, a process likely mediated by the SCF p45Skp2 pathway, and this ultimately targets B-Myb to rapid degradation. BMyb domains: DNA binding domain (purple); transactivation domain (red) ing the ECF detection kit (Amersham) and scanning on a PhosphorImager model Storm 960 (Molecular Dynamics). Data were acquired and processed using ImageQuaNT 2 software (Molecular Dynamics).
Immunoprecipitations were carried out for 3 h at 48C in Buer A using equal amounts of total protein (100 ± 300 mg), 5 ml B-Myb antiserum (Kamano et al., 1995) or 2 mg of p45 Skp2 antibody. The amount of protein that underwent immunoprecipitation was corrected for transfection eciency. Antibodies were immobilized on protein A-or protein GSepharose beads, the resin was washed with 361 ml ice-cold Buer A and proteins were resolved as described above. When indicated, immunoprecipitates were resuspended with 56 concentrated Buer C (80 mM Tris-HCl, pH 6.8, 19.3 mg/ml iodoacetamide, 10% glycerol, 2% SDS, 0.2% bromophenol blue) and heated at 808C for 3 min to prevent denaturation of the immunoglobulins and eliminate the signal given by the heavy chain (*50 kDa) in subsequent Western blot analysis.
Northern blot analysis
Total RNA was isolated from HEK 293 cells using TRIzol reagent (Life Tech.) following the manufacturer's instructions. The RNA quality was examined upon resolution of an aliquot on 1% agarose gel followed by staining with ethidium bromide. For analysis, 30 mg of RNA were size fractionated through a formaldehyde/agarose gel (1.2%), and blotted onto a nylon membrane (Boehringer Mannheim). Pre-hybridization and hybridization were carried out at 658C in 250 mM sodium phosphate buer (pH 7.2), 1 mM EDTA, 7% SDS. The membrane was washed to a ®nal stringency of 1% SDS, in 40 mM sodium phosphate buer (pH 7.2), 1 mM EDTA. B-Myb and b-actin probes were labeled with a-32 P-dCTP (3000 Ci/mmol, Amersham) using a random primer labeling kit (Amersham). Probes were puri®ed using NucTrap 1 probe puri®cation columns (Stratagene).
Immunofluorescence
Indirect immuno¯uorescence experiments were performed with REF52 cells that were grown on acid-washed glass coverslips as described (Charrasse et al., 1999) . Brie¯y, 16 h after transfection cells expressing full-length or C-terminally deleted B-Myb were washed with PBS, ®xed in 7208C methanol for 4 min. Coverslips were incubated for 60 min at 378C in 1% BSA-PBS containing the primary antibody (2 mg/ ml B-Myb N-19, S. Cruz Biotech). After washing with PBS, uorescein-conjugated donkey anti-rabbit IgG (Amersham, 1 : 50 in 1% BSA-PBS) was added to the cells for an additional 45 min at 378C. The secondary antibody was combined with Hoechst dye (Sigma, 2 mg/ml) to stain DNA. Coverslips were mounted in FluorSave (Calbiochem). Cells were observed with an Axioplan microscope (Zeiss) equipped with a 100 W HBO lamp for¯uorescence. High-resolution pictures were taken with oil-immersion lenses (63XNA). Images were captured with a color-chilled 3CCD camera (Hamamatsu, model C5810).
